AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read

Freedom Capital Markets maintains Buy rating on iRhythm Holdings, $190 price target

Freedom Capital Markets kept a Buy rating and $190 price target on iRhythm Holdings, implying 74.2% upside from the Oct 5 close. The firm expects $1B+ revenue by 2027, 70%+ gross margin, and 15%+ EBITDA margin. The VitalConnect acquisition could add $65M in revenue within 12 months.

Original reporting
tradingview.com
Published Oct 6, 2026, 12:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Freedom Capital Markets maintains Buy rating on iRhythm Holdings, $190 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The maintained Buy rating and $190 target suggest a strong bullish outlook, potentially prompting short-term buying.

02

Market read

New analyst rating and price target provide fresh actionable information for traders.

03

What to watch

No discussion of competitive pressures or regulatory hurdles in the cardiac monitoring space.

Relevance 6/10Novelty 5/10Timing: today

Background

Analyst note from Freedom Capital Markets on iRhythm Holdings (IRHM).

Market effects

Sector

Potential uplift for the ambulatory cardiac monitoring sector as the upgrade highlights growth prospects.

Regional

Limited to U.S. markets where the stock trades.

Global

Minimal global impact beyond the company's niche.

Counterpoint

What could challenge this read

The target assumes successful integration of VitalConnect; integration risks could temper upside.

Key entities

  • Company
    iRhythm Holdings

    Provider of ambulatory cardiac monitoring solutions.

  • Analyst
    Freedom Capital Markets

    Equity research firm issuing the rating.

Read at source← All news

Related articles

OCT 7
MedAI 8/10

iRhythm Completes VitalConnect Acquisition

iRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.

hoodline.com3 min
OCT 5
$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

investing.com2 min
OCT 5
$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

SEC EDGAR 8-K2 min
OCT 5
$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.

globenewswire.com3 min